Onyx Pharmaceuticals Inc. - Articles and news items


Amgen announces top-line results from Phase 3 focus trial of kyprolis® in patients with relapsed and advanced refractory multiple myeloma

Industry news / 15 August 2014 / Amgen

Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., announced that the Phase 3 clinical trial FOCUS did not meet its primary endpoint of improving overall survival…


Amgen and Onyx Data at ASCO 2014 highlight oncology pipeline and portfolio

Industry news / 28 May 2014 / Amgen

New data reinforces commitment to personalized medicine and highlights advances in immunotherapy platform…


Bayer and Onyx report Phase 3 study results of NEXAVAR® (sorafenib) as adjuvant treatment for patients with liver cancer who have undergone surgery or local ablation

Industry news / 11 March 2014 / Amgen

Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., announced that a Phase 3 trial evaluating the investigational use of NEXAVAR® (sorafenib) tablets as an adjuvant treatment for patients with hepatocellular carcinoma…

Amgen logo
Amgen logo

Amgen and Onyx Pharmaceuticals announce early termination of HSR waiting period

Industry news, News / 18 September 2013 / Amgen

Amgen and Onyx Pharmaceuticals have announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR), in connection with Amgen’s proposed acquisition of Onyx, was terminated early on Sept. 18, 2013…

Amgen logo

Amgen to acquire Onyx Pharmaceuticals for $125 per share in cash

Industry news, News / 25 August 2013 / Amgen

Amgen will acquire all of the outstanding shares of Onyx for $125 per share in cash…

Bayer logo

Nexavar in combination with chemotherapy improves progression-free survival in patients with advanced breast cancer in Phase 2 study

Industry news, News / 18 May 2011 / OGILVY PR WORLDWIDE

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. announced results from a Phase 2b trial…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...